Inventiva Pharma
Update in progressIVA (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on oral small-molecule therapies for metabolic and fibrotic diseases. It develops Lanifibranor, a pan-PPAR agonist in NATiV3 Phase 3 for MASH; Odiparcil for mucopolysaccharidoses; and a preclinical TGF-β program for idiopathic pulmonary fibrosis. Founded in 2011, the company is headquartered in Daix, France, with international activity.
Company score
- Sentiment
- 0.32
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.19
- Governance
- 0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.19
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationFrance
- Founded2011
- Employees69
- Websiteinventivapharma.com
Identifiers
- ISINUS46124U1079
- FIGIBBG00VM4C335
- CIK0001756594